Oculis (OCS) Competitors $19.24 +0.22 (+1.16%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$19.01 -0.23 (-1.20%) As of 06/16/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCS vs. PTGX, SRRK, ALVO, MTSR, CPRX, VKTX, KYMR, CRNX, MLTX, and MORShould you be buying Oculis stock or one of its competitors? The main competitors of Oculis include Protagonist Therapeutics (PTGX), Scholar Rock (SRRK), Alvotech (ALVO), Metsera (MTSR), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), MoonLake Immunotherapeutics (MLTX), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry. Oculis vs. Its Competitors Protagonist Therapeutics Scholar Rock Alvotech Metsera Catalyst Pharmaceuticals Viking Therapeutics Kymera Therapeutics Crinetics Pharmaceuticals MoonLake Immunotherapeutics MorphoSys Protagonist Therapeutics (NASDAQ:PTGX) and Oculis (NASDAQ:OCS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, community ranking, media sentiment, risk and dividends. Is PTGX or OCS more profitable? Protagonist Therapeutics has a net margin of 52.76% compared to Oculis' net margin of -8,043.28%. Protagonist Therapeutics' return on equity of 34.68% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Protagonist Therapeutics52.76% 34.68% 30.98% Oculis -8,043.28%-71.31%-56.85% Do institutionals and insiders believe in PTGX or OCS? 98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 4.9% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, PTGX or OCS? Protagonist Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500. Comparatively, Oculis has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Which has stronger valuation & earnings, PTGX or OCS? Protagonist Therapeutics has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtagonist Therapeutics$207.80M16.30-$78.96M$0.7572.88Oculis$980K857.20-$98.92M-$2.64-7.29 Do analysts rate PTGX or OCS? Protagonist Therapeutics currently has a consensus target price of $65.44, suggesting a potential upside of 19.73%. Oculis has a consensus target price of $35.33, suggesting a potential upside of 83.65%. Given Oculis' higher probable upside, analysts plainly believe Oculis is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Oculis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in PTGX or OCS? Protagonist Therapeutics received 260 more outperform votes than Oculis when rated by MarketBeat users. However, 91.89% of users gave Oculis an outperform vote while only 61.64% of users gave Protagonist Therapeutics an outperform vote. CompanyUnderperformOutperformProtagonist TherapeuticsOutperform Votes29461.64% Underperform Votes18338.36% OculisOutperform Votes3491.89% Underperform Votes38.11% Does the media prefer PTGX or OCS? In the previous week, Protagonist Therapeutics had 5 more articles in the media than Oculis. MarketBeat recorded 8 mentions for Protagonist Therapeutics and 3 mentions for Oculis. Protagonist Therapeutics' average media sentiment score of 1.01 beat Oculis' score of -0.23 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Protagonist Therapeutics Positive Oculis Neutral SummaryProtagonist Therapeutics beats Oculis on 15 of the 18 factors compared between the two stocks. Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCS vs. The Competition Export to ExcelMetricOculisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$840.06M$6.78B$5.52B$8.60BDividend YieldN/A2.46%5.27%4.17%P/E Ratio-9.978.3626.5319.77Price / Sales857.20262.40405.95150.25Price / CashN/A65.8538.2534.64Price / Book6.706.567.054.68Net Income-$98.92M$142.76M$3.21B$247.80M7 Day Performance-2.78%-2.02%-0.24%-0.45%1 Month Performance7.79%8.22%7.34%3.94%1 Year Performance63.05%4.65%34.89%16.00% Oculis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCSOculis1.9168 of 5 stars$19.24+1.2%$35.33+83.6%+63.1%$840.06M$980K-9.972Short Interest ↑PTGXProtagonist Therapeutics2.1865 of 5 stars$55.68+2.4%$65.44+17.5%+63.7%$3.45B$207.80M20.93120Positive NewsSRRKScholar Rock4.3933 of 5 stars$34.07-0.5%$42.67+25.2%+240.0%$3.23B$33.19M-14.50140Positive NewsALVOAlvotech1.7688 of 5 stars$10.63-0.3%$18.00+69.3%-33.5%$3.21B$585.60M-5.754Short Interest ↑MTSRMetseraN/A$30.39+10.5%$47.00+54.7%N/A$3.19BN/A0.0081Gap UpHigh Trading VolumeCPRXCatalyst Pharmaceuticals4.7799 of 5 stars$25.84-0.1%$32.83+27.1%+57.2%$3.15B$534.65M21.9080VKTXViking Therapeutics4.4887 of 5 stars$27.57-0.9%$87.15+216.1%-48.2%$3.10BN/A-27.5720Positive NewsGap UpKYMRKymera Therapeutics3.4605 of 5 stars$47.16-1.0%$59.82+26.9%+40.7%$3.07B$58.89M-20.15170CRNXCrinetics Pharmaceuticals3.3927 of 5 stars$32.28-2.2%$74.56+131.0%-31.2%$3.02B$760K-8.65210News CoveragePositive NewsInsider TradeMLTXMoonLake Immunotherapeutics1.9009 of 5 stars$46.62-0.6%$78.71+68.8%+3.6%$2.98BN/A-36.142MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730 Related Companies and Tools Related Companies PTGX Competitors SRRK Competitors ALVO Competitors MTSR Competitors CPRX Competitors VKTX Competitors KYMR Competitors CRNX Competitors MLTX Competitors MOR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCS) was last updated on 6/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWill I be blacklisted?The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OCS Stock Free OCS Stock Alerts